SciCombinator

Discover the most talked about and latest scientific content & concepts.

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

OPEN The New England journal of medicine | 12 Dec 2012

CJ Ryan, MR Smith, JS de Bono, A Molina, CJ Logothetis, P de Souza, K Fizazi, P Mainwaring, JM Piulats, S Ng, J Carles, PF Mulders, E Basch, EJ Small, F Saad, D Schrijvers, H van Poppel, SD Mukherjee, H Suttmann, WR Gerritsen, TW Flaig, DJ George, EY Yu, E Efstathiou, A Pantuck, E Winquist, CS Higano, ME Taplin, Y Park, T Kheoh, T Griffin, HI Scher and DE Rathkopf
Abstract
Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. Methods In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. Results The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone-prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P=0.01) but did not cross the efficacy boundary. Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with abiraterone-prednisone. Conclusions Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198 .).
Tweets*
110
Facebook likes*
4
Reddit*
0
News coverage*
3
Blogs*
7
SC clicks
4
Concepts
Androgen, Prostate-specific antigen, Radiation therapy, Oncology, Chemotherapy, Metastasis, Cancer, Prostate cancer
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com